GLP-1 based therapies and disease course of inflammatory bowel disease
Authors:
Open Access
- 1 July 2021
- journal article
- research article
- Published by Elsevier in eClinicalMedicine
- Vol. 37, 100979
Abstract
No abstract availableKeywords
Funding Information
- Danmarks Grundforskningsfond (DNRF148)
- Novo Nordisk Fonden (NNF16OC0022586, NNF17OC0029768)
This publication has 31 references indexed in Scilit:
- Crohn's diseaseThe Lancet, 2012
- Bias in Observational Studies of Prevalent Users: Lessons for Comparative Effectiveness Research From a Meta-Analysis of StatinsAmerican Journal of Epidemiology, 2012
- Ulcerative ColitisNew England Journal of Medicine, 2011
- Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?Trends in Pharmacological Sciences, 2009
- Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in miceFrontiers in Bioscience-Landmark, 2008
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) StatementEpidemiology, 2007
- Dual Inhibition of Dipeptidyl Peptidase IV and Aminopeptidase N Suppresses Inflammatory Immune ResponsesAnnals of the New York Academy of Sciences, 2007
- Inflammatory Bowel DiseaseNew England Journal of Medicine, 2002
- Dipeptidyl Peptidase IV (DP IV, CD26) in Patients with Inflammatory Bowel DiseaseScandinavian Journal of Gastroenterology, 2001
- Assessment of the Diagnoses of Crohn's Disease and Ulcerative Colitis in a Danish Hospital Information SystemScandinavian Journal of Gastroenterology, 1996